Tonix Presents at Neuroscience & Biotech Conferences, Showcasing Fibromyalgia Treatment
Tonix Pharmaceuticals Holding Corp. (Tonix), a biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges, is actively engaging with investors at several key industry conferences in January 2025. The company is strategically presenting its research and development pipeline and engaging with potential partners, highlighting its diverse portfolio of product candidates. These meetings represent a significant opportunity for Tonix to advance its core therapeutic areas, including fibromyalgia, acute stress reactions, cocaine intoxication, and autoimmune diseases. Specifically, Tonix management will be presenting at the 8th Annual Neuroscience Innovation Forum by Sachs Associates, the 2025 Biotech Showcase, and hosting individual meetings arranged through the respective conference coordinators. This proactive engagement underscores the company’s commitment to generating interest in its innovative approaches to neurological and immunological disorders.
Neuroscience Innovation Forum Presentation
Tonix will be presenting a detailed overview of its research and development efforts at the 8th Annual Neuroscience Innovation Forum, hosted by Sachs Associates, on Sunday, January 12, 2025, at the Marines Memorial Club in San Francisco. Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will lead the presentation, focusing on the company’s revolutionary neuropsychiatric treatment strategies. The session, titled “Revolutionizing Neuropsychiatric Treatments: Novel Approaches,” will be held in Track A – Room Rosenberg and is scheduled for 11:15 a.m. PT. This presentation aims to showcase the company’s commitment to advancing therapies for conditions affecting the central nervous system. Following the presentation, attendees will have the opportunity to engage directly with the Tonix leadership team.
2025 Biotech Showcase Participation
Furthermore, Tonix will participate in the 2025 Biotech Showcase on Tuesday, January 14, 2025, at the Hilton San Francisco Union Square in San Francisco. Again, Seth Lederman, M.D., will lead the company’s presentation, concentrating on its potential to address critical medical needs. The session, “2025 Biotech Showcase,” will take place in Yosemite C (Ballroom level) at 10:00 a.m. PT. This event provides a platform for Tonix to present its broader research initiatives and discuss potential collaborations within the biotechnology sector. The presentation will cover key areas such as the development of TNX-102 SL, a product candidate designed for the management of fibromyalgia, alongside explorations into acute stress disorder treatment and cocaine intoxication.
Investor Engagement and Meeting Scheduling
Tonix is facilitating individual investor meetings at both the Neuroscience Innovation Forum and the Biotech Showcase. Interested investors are encouraged to contact the respective conference coordinators to arrange a direct meeting with Tonix management. These individual meetings will allow for more in-depth conversations about the company’s strategic vision, clinical trial data, and long-term growth prospects. This targeted approach demonstrates Tonix’s dedication to fostering strong relationships with investors and partners.
Key Product Development Initiatives
Tonix’s product development pipeline focuses on several high-priority programs. TNX-102 SL, its lead candidate for fibromyalgia, is nearing a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, following the submission of a New Drug Application (NDA) based on statistically significant Phase 3 clinical studies. The FDA has granted this candidate Fast Track designation, signifying priority review. Beyond fibromyalgia, Tonix is also developing TNX-102 SL for acute stress reaction and acute stress disorder, currently under a Physician-Initiated IND at the University of North Carolina, funded by the U.S. Department of Defense (DoD). Moreover, the company is advancing TNX-13000, a biologic designed to treat cocaine intoxication, which has received Breakthrough Therapy designation from the FDA and is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology portfolio incorporates TNX-1500, an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), aimed at preventing allograft rejection and treating autoimmune diseases.
Expanding Research and Strategic Partnerships
In addition to these core programs, Tonix is also pursuing research in rare diseases, including treatment for Prader-Willi syndrome, and infectious diseases, most notably a vaccine for mpox (TNX-801). Recently, Tonix secured a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45, for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix operates a state-ofart infectious disease research facility in Frederick, Md., and its commercial subsidiary, Tonix Medicines, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
Concluding, Tonix Pharmaceuticals’ strategic participation in key industry conferences, coupled with its diverse product development pipeline, underscores its commitment to transforming therapies for significant unmet medical needs across pain management, neurological disorders, and infectious diseases. The company’s proactive engagement with investors and ongoing research initiatives position it for continued growth and innovation within the biopharmaceutical sector.
